| Domain | Key findings | Ontology / identifier suggestions | Key statistics / notes | Evidence |
|---|---|---|---|---|
| Definition / identifiers | MICPCH = microcephaly with pontine and cerebellar hypoplasia; rare X-linked neurodevelopmental disorder within the CASK-related disorder spectrum, usually defined at disease level from aggregated resources plus patient-level case/cohort reports. OMIM explicitly cited as **300749** in recent literature. | OMIM: 300749; Gene: **CASK**; disease label: microcephaly with pontine and cerebellar hypoplasia syndrome | 2023 review summarized 49 reports and 197 patients across CASK-related disorders. | (pqac-00000005, pqac-00000006) |
| Cause / inheritance | Primary cause is **loss-of-function or hypomorphic pathogenic variants in CASK** on Xp11.4; includes nonsense, frameshift/indel, splice, missense, and copy-number loss. Inheritance is usually **de novo X-linked dominant** in females; hemizygous males are often much more severely affected, and **somatic mosaicism** can permit survival with milder disease in males. | HGNC gene suggestion: CASK; inheritance: X-linked dominant / X-linked semidominant; variant consequence: loss of function | In 41-patient MICPCH cohort, causative/candidate aberrations in **37/41 (90.2%)**; **32/41** involved CASK, including **23 point mutations** and **9 CNVs**. | (pqac-00000002, pqac-00000003, pqac-00000007) |
| Hallmark phenotypes and frequencies | Core phenotype: severe developmental delay/intellectual disability, postnatal progressive microcephaly, hypotonia or motor disorder, and pontocerebellar hypoplasia. Additional features can include dystonia, scoliosis, epilepsy, ophthalmologic abnormalities, hearing loss, growth retardation, and feeding difficulties. Suggested HPO terms: Microcephaly (HP:0000252), Progressive microcephaly (HP:0000253), Cerebellar hypoplasia (HP:0001321), Pontine hypoplasia (HP:0007366), Global developmental delay (HP:0001263), Severe intellectual disability (HP:0010864), Seizure (HP:0001250), Hypotonia (HP:0001252), Dystonia (HP:0001332), Sensorineural hearing impairment (HP:0000407), Optic atrophy/hypoplasia (HP:0000648/HP:0008058), Feeding difficulties (HP:0011968), Scoliosis (HP:0002650). | HPO terms as listed | Burglen 2012: **13/14** screened PCH patients had CASK abnormalities; in those 13, epilepsy in **4/13**, hearing loss in **2/13**; severe microcephaly **< -6 SD in 7**, **-3 to -4 SD in 4**. Hayashi 2017: only **6/41** could walk and **3/41** could speak. Review-level estimate: seizures occur in about **40%** of cases. | (pqac-00000000, pqac-00000001, pqac-00000002) |
| MRI / neuroradiology | Typical MRI shows **pontine and cerebellar hypoplasia**, often with variable vermian and hemispheric involvement and relative preservation of supratentorial structures compared with classic neurodegenerative PCH. Corpus callosum is often normal or relatively spared; a low brain-to-corpus-callosum ratio has been suggested as a clue to CASK-related disease. | UBERON suggestions: cerebellum (UBERON:0002037), pons (UBERON:0000988), corpus callosum (UBERON:0000955), brainstem (UBERON:0002298) | van Dijk 2021 included **6 MICPCH** patients and found severe cerebellar hypoplasia at birth with nearly absent postnatal growth, but without the caudate/ventricular changes seen in PCH1B/PCH2A. Burglen 2012 found universal brainstem/cerebellar hypoplasia in affected individuals. | (pqac-00000001, pqac-00000005) |
| Diagnosis | Diagnosis is clinical-radiologic plus molecular: suspect in infants/children, especially females, with postnatal progressive microcephaly, severe developmental delay, and PCH-like MRI. Recommended testing emphasizes **broad genomic testing** (WES/WGS or neurodevelopmental/PCH panels) plus CNV analysis because both sequence variants and deletions occur. Differential diagnosis includes other genetic causes of radiologic PCH and non-CASK monogenic/chromosomal etiologies. | Diagnostic concepts: WES, WGS, CNV analysis, multigene panel; HPO-driven genomic analysis | Hayashi 2017 showed high yield with combined genomic investigation: **37/41 (90.2%)** solved/candidate; Zakaria 2024 emphasized broad testing because classic OMIM-listed PCH genes explain only a minority of radiologic PCH cases. | (pqac-00000002, pqac-00000003) |
| Mechanism / pathophysiology | CASK is a **MAGUK scaffold protein** with CaMK, L27, PDZ, SH3, and GuK domains and roles in synaptic organization, protein interactions, and nuclear transcriptional regulation (including TBR1/CINAP-related pathways affecting **GRIN2B/GluN2B** and **RELN**). Human and mouse evidence supports a mixed mechanism: developmental hindbrain malformation plus **post-developmental cerebellar granule-cell vulnerability/degeneration**; neuronal CASK deficiency can also disrupt **excitatory/inhibitory synaptic balance** via GluN2B downregulation, and metabolic stress/oxidative metabolism defects may contribute. Suggested GO terms: synapse organization, regulation of excitatory postsynaptic potential, cerebellar granule cell development/survival, regulation of gene expression, cellular respiration. Suggested CL terms: cerebellar granule cell, Purkinje cell, cortical pyramidal neuron, astrocyte. | GO / CL suggestions as listed; cellular compartments: synapse, nucleus, cytoplasm | Mori 2019 showed GluN2B rescue corrected E/I imbalance in CASK-deficient neurons. Srivastava 2016 suggested non-cell-autonomous postnatal brain growth effects and metabolic abnormalities. Patel 2024 supports splice-dependent forebrain vs hindbrain functional differences. | (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000012, pqac-00000013) |
| Management / real-world care | No disease-modifying therapy is established. Current care is **supportive and multidisciplinary**: developmental therapies, nutritional/feeding support, seizure management, audiology/hearing support, ophthalmology, orthopedic monitoring for scoliosis, and genetic counseling. | NCIT suggestions: Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Anticonvulsant Therapy, Gastrostomy, Hearing Aid Device, Genetic Counseling | Clinical-trial search identified **no relevant interventional MICPCH/CASK trials** in available tool output. Preclinical concepts (e.g., targeting GluN2B pathways or metabolic dysfunction) remain experimental, not standard care. | (pqac-00000000, pqac-00000010, pqac-00000011) |
| Prognosis / outcomes | Prognosis is dominated by lifelong severe neurodevelopmental impairment. Females often have a non-progressive or slowly evolving developmental encephalopathy after early postnatal decline in head growth, whereas hemizygous males may have profound encephalopathy, refractory epilepsy, and respiratory/swallowing complications. Functional outcomes are commonly poor, with major limitations in ambulation and speech. | Outcome concepts: severe developmental disability, epilepsy, feeding impairment | Hayashi 2017: **6/41** walked and **3/41** spoke. Burglen 2012 described a severely affected hemizygous boy with refractory epilepsy and a milder mosaic male. Robust disease-specific life expectancy statistics are not available from the retrieved evidence. | (pqac-00000000, pqac-00000001, pqac-00000002) |
| Evidence gaps | Major gaps remain in prevalence/incidence, penetrance estimates, genotype-specific prognosis, quality-of-life metrics, validated biomarkers, standardized treatment algorithms, and controlled therapeutic studies. Recent mechanistic work is largely preclinical, and direct human multi-omics or longitudinal natural-history datasets are limited. | Data gap annotation; future ontology mapping could add MONDO/Orphanet when confirmed from source databases | No reliable population prevalence, carrier frequency, or survival curves were found in the retrieved evidence; no established preventive medical intervention beyond reproductive genetic counseling/testing. | (pqac-00000002, pqac-00000006, pqac-00000008) |


*Table: This compact table summarizes the core knowledge-base elements for MICPCH syndrome, including definition, genetics, phenotype, imaging, diagnosis, mechanism, management, prognosis, and current evidence gaps. It highlights study-level statistics and ontology suggestions while staying within the available evidence.*